Spinal cancer combo therapy study ends early after just one patient
NCT ID NCT05204290
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This early-stage study tested whether combining precise radiation to the spine with the immunotherapy drug pembrolizumab is feasible for people with advanced spinal tumors pressing on the spinal cord. Only one person enrolled before the study was stopped early. The goal was to see if patients could complete both treatments safely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.